NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Zogenix Inc. (LSE: 0M3O)

 
0M3O Technical Analysis
5
As on 2nd Mar 2022 0M3O STOCK Price closed @ 26.37 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4.17 & Strong Buy for SHORT-TERM with Stoploss of 17.19 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

0M3OSTOCK Price

Open 26.37 Change Price %
High 26.37 1 Day 0.18 0.69
Low 26.37 1 Week 0.42 1.62
Close 26.37 1 Month 10.67 67.96
Volume 300 1 Year 11.87 81.86
52 Week High 26.37 | 52 Week Low 11.19
 
LSE UK Most Active Stocks
SYME 0.00 %
PREM 0.04 0.00%
UKOG 0.01 0.00%
VRS 0.04 0.00%
ENET 0.03 0.00%
VAST 0.36 -10.00%
DEMG 0.02 -50.00%
SMDS 582.50 0.00%
DKE 0.15 0.00%
NNN 0.09 50.00%
 
LSE UK Top Gainers Stocks
0YY7 20.40 280.60%
SSIF 18.50 208.33%
CGW 55.03 107.66%
GILD 0.08 100.00%
GILD 0.08 100.00%
GILD 0.08 100.00%
CNN 65.00 85.71%
VENC 139.60 65.21%
CMO 5.50 57.14%
CMO 5.50 57.14%
 
LSE UK Top Losers Stocks
DNA 0.06 -99.90%
DNA 0.06 -99.90%
DNA 0.06 -99.90%
DNA 0.06 -99.90%
JPE 12.55 -98.66%
SPPC 0.15 -93.75%
0QQO 94.50 -89.33%
AGM 1.00 -80.95%
AGM 1.00 -80.95%
AGM 1.00 -80.95%
 
 
0M3O
Daily Charts
0M3O
Intraday Charts
Whats New @
Bazaartrend
0M3O
Free Analysis
 
0M3O Important Levels Intraday
RESISTANCE26.37
RESISTANCE26.37
RESISTANCE26.37
RESISTANCE26.37
RESISTANCE26.37
RESISTANCE26.37
RESISTANCE26.37
RESISTANCE26.37
 
0M3O Forecast April 2025
4th UP Forecast55.99
3rd UP Forecast46.49
2nd UP Forecast40.62
1st UP Forecast34.75
1st DOWN Forecast17.99
2nd DOWN Forecast12.12
3rd DOWN Forecast6.25
4th DOWN Forecast-3.25
 
0M3O Weekly Forecast
4th UP Forecast28.16
3rd UP Forecast27.59
2nd UP Forecast27.23
1st UP Forecast26.88
1st DOWN Forecast25.86
2nd DOWN Forecast25.51
3rd DOWN Forecast25.15
4th DOWN Forecast24.58
 
0M3O Forecast2025
4th UP Forecast55.99
3rd UP Forecast46.49
2nd UP Forecast40.62
1st UP Forecast34.75
1st DOWN Forecast17.99
2nd DOWN Forecast12.12
3rd DOWN Forecast6.25
4th DOWN Forecast-3.25
 
Zogenix Inc. ( LSE UK Symbol : 0M3O )
Sector : N/A And Other Stocks in Same Sector
 
0M3O Other Details
Segment EQ
Market Capital 1839968512.00
Sector
Industry
Offical website >
 
0M3O Address
0M3O
 
0M3O Latest News
 
Your Comments and Response on Zogenix Inc.
 
0M3O Business Profile
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California. Address: 5959 Horton Street, EmeryVille, CA, United States, 94608
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service